KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other financing activities (2013 - 2025)

Sarepta Therapeutics' quarterly Other financing activities came in at $14.8 million in Q4 2025, up 2568.59% quarter-over-quarter from $554000.0 in Q4 2022.

Sarepta Therapeutics has reported Other financing activities for 7 years, with the latest figure at $14.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to $14.8 million; the trailing twelve-month figure through Dec 2025 stood at $15.3 million (up 2668.59% YoY), and the FY2025 full-year result was $17.1 million, changed N/A from the prior year.
  • Other financing activities for Q4 2025 stood at $14.8 million, up from $554000.0 in the prior quarter.
  • The five-year high for Other financing activities was $14.8 million in Q4 2025, with the low at $554000.0 in Q4 2022.
  • Average Other financing activities over 3 years is $5.6 million, with a median of $1.4 million recorded in 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Sarepta Therapeutics 1.86 Bn 1.17 Bn 291.52 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 14.78 Mn
Dec 31, 2025 14.78 Mn
Dec 31, 2022 554,000.00
Dec 31, 2022 554,000.00
Jun 30, 2021 1.43 Mn
Jun 30, 2021 1.43 Mn
Sep 30, 2019 3.45 Mn
Sep 30, 2019 3.45 Mn
Mar 31, 2019 889,000.00
Mar 31, 2019 889,000.00
Sep 30, 2018 3.30 Mn
Sep 30, 2018 3.30 Mn
Jun 30, 2018 5.75 Mn
Jun 30, 2018 5.75 Mn
Dec 31, 2015 -618,000.00
Dec 31, 2015 -618,000.00
Dec 31, 2013 404,000.00
Dec 31, 2013 404,000.00